Sichuan Kelun-Biotech Biopharmaceutical Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
Sichuan Kelun-Biotech Biopharmaceutical is forecast to grow earnings and revenue by 7.6% and 24.6% per annum respectively. EPS is expected to grow by 6.4% per annum. Return on equity is forecast to be -1.2% in 3 years.
Wichtige Informationen
7.6%
Wachstumsrate der Gewinne
6.4%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 41.8% |
| Wachstumsrate der Einnahmen | 24.6% |
| Zukünftige Eigenkapitalrendite | -1.2% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 22 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 21
Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results
Mar 27Recent updates
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 21We Think Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Can Easily Afford To Drive Business Growth
Jun 14Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results
Mar 27An Intrinsic Calculation For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Suggests It's 45% Undervalued
Jan 11Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 2,591 | -163 | -122 | 57 | 15 |
| 12/31/2025 | 1,663 | -622 | -496 | -392 | 15 |
| 12/31/2024 | 1,827 | -246 | -473 | -518 | 15 |
| 6/30/2024 | 1,877 | -187 | -567 | -480 | N/A |
| 3/31/2024 | 1,709 | -354 | -295 | -210 | N/A |
| 12/31/2023 | 1,540 | -522 | -23 | 60 | N/A |
| 9/30/2023 | 1,523 | -427 | 135 | 207 | N/A |
| 6/30/2023 | 1,505 | -333 | 292 | 355 | N/A |
| 3/31/2023 | 1,155 | -440 | -9 | 42 | N/A |
| 12/31/2022 | 804 | -548 | -310 | -271 | N/A |
| 12/31/2021 | 32 | -823 | -581 | -486 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 6990 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Ertrag vs. Markt: 6990 is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hohe Wachstumserträge: 6990 is expected to become profitable in the next 3 years.
Einnahmen vs. Markt: 6990's revenue (24.6% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).
Hohe Wachstumseinnahmen: 6990's revenue (24.6% per year) is forecast to grow faster than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 6990 is forecast to be unprofitable in 3 years.